SK bioscience

Balance sheet - Sort, 1st period(2018.12.31), 2nd period(2019.12.31), 3rd period(2020.12.31), 4rd period(2021.12.31)
Sort	1st period (2018.07.01-2018.12.31)	2nd period (2019.01.01-2019.12.31)	3rd period (2020.01.01-2020.12.31)	4rd period (2021.01.01-2021.12.31)
Liquid assets	180,729	170,741	333,902	1,837,804
Cash and cash equivalents	4,489	14,380	24,972	98,028
Short-term financial investment	99,189	80,088	183,736	1,547,635
Receivables	43,472	32,429	45,838	48,134
Inventory assets	31,876	36,379	70,275	135,045
Other inventory assets	1,650	7,465	782	8,508
Contract asset	0	0	980	0
Derivative financial assets	53	0	128	451
Non-current assets	219,268	233,239	228,330	272,318
Long-term financial investment	10,985	10,597	0	21,609
Deposit	356	348	455	690
Tangible assets	172,831	182,477	180,992	210,264
Copy right assets	0	8,293	8,487	10,718
Intangible assets	21,839	19,479	17,858	17,061
Other liquid assets	85	85	95	91
Derivative financial assets	0	65	0	1,639
Deferred tax asset	13,172	11,895	20,443	10,241
Total	399,997	403,980	562,232	2,110,123

Liabilities - Sort, 1st period(2018.12.31), 2nd period(2019.12.31), 3rd period(2020.12.31), 4rd period(2021.12.31)
Sort	1st period (2018.07.01-2018.12.31)	2nd period (2019.01.01-2019.12.31)	3rd period (2020.01.01-2020.12.31)	4rd period (2021.01.01-2021.12.31)
Liquid liabilities	50,610	45,509	108,640	459,952
Purchased and other liabilities	25,542	31,613	39,153	102,184
Liquidity bond	0	0	10,995	47,977
Long-term liquidity loan	11,250	0	0	11,671
Liquidity lease	161	1,351	1,614	2,309
Other liquidity bond	8,374	7,780	28,640	94,638
Liquidity contract liabilities	5,283	4,687	94,899	98,789
Derivative financial liabilities	0	0	75	894
Corporate tax liabilities (Current period)	0	78	5,264	101,485
Non-current liabilities	130,142	125,737	117,802	48,858
Private bonds	92,196	93,473	80,473	35,502
Long-term loans	34,353	23,156	21,760	0
Lease	0	7,093	7,126	8,774
Defined-benefit liabilities	1,774	2,015	4,358	4,246
Derivative financial liabilities	1,819	0	3,617	0
Other non-current liabilities	0	0	468	335
Total	180,752	171,246	298,442	508,811

Capital - Sort, 1st period(2018.12.31), 2nd period(2019.12.31), 3rd period(2020.12.31), 4rd period(2021.12.31)
Sort	1st period (2018.07.01-2018.12.31)	2nd period (2019.01.01-2019.12.31)	3rd period (2020.01.01-2020.12.31)	4rd period (2021.01.01-2021.12.31)
Gross capital	10,200	10,200	30,600	38,250
Capital surplus	201,219	201,219	180,518	1,157,063
Other capital	25	325	901	900
Accumulated income	(1,242)	(1,319)	-1,465	(207)
Retained earnings	9,043	22,309	53,236	405,305
Total	219,245	232,734	263,790	1,601,311

Income statement - Sort, 1st period(2018.07.01-2018.12.31), 2nd period(2019.01.01-2019.12.31), 3rd period(2020.01.01-2020.12.31), 4rd period(2021.01.01-2021.12.31)
Sort	1st period (2018.07.01-2018.12.31)	2nd period (2019.01.01-2019.12.31)	3rd period (2020.01.01-2020.12.31)	4rd period (2021.01.01-2021.12.31)
Sales profits	99,403	183,938	225,611	929,001
Sales costs	48,958	106,078	130,269	358,718
Sales total	50,445	77,860	95,342	570,283
Sales & maintenance costs	24,009	55,063	57,632	96,063
Profits	26,436	22,797	37,710	474,220
Other profits	99	144	3,742	5,159
Other expenses	12,937	1,934	1,909	2,849
Financial revenues	1,303	5,184	7,903	26,241
Financial expenses	2,807	7,706	10,153	31,643
Net income (Including corporate tax)	12,094	18,485	37,293	471,128
Corporate tax	3,161	3,808	4,403	115,989
Net income (Current period)	8,933	14,677	32,890	355,139
Other comprehensive income	(173)	(1,489)	-2,108	(1,813)
Other comprehensive income (that is subsequently reclassified as profit or loss)	0	0	0	0
Derivative revenues	(283)	(77)	-146	1,257
Other comprehensive income (that is subsequently unclassified as profit or loss)	0	0	0	0
Remeasurement of defined expenses	110	(1,412)	-1,962	(3,070)
Accumulated other comprehensive income	8,760	13,188	30,782	353,326
Basic profits / shares	149	240	537	4,844
Diluted EPS	0	0	533	4,810

IR